FOXC2 and nonpapillary renal cell carcinoma: There were no significant differences in the frequencies of the six candidate aggressiveness-associated mutations in patients with aggressive ccRCC and those without aggressive ccRCC (Table S3); however, for the patients with aggressive ccRCC, BAP1, KDM5C, and FOXC2 mutations were enriched by two-fold, and CLIP4 mutations were enriched by three-fold, compared to that in patients without aggressive ccRCC.